Breaking News

Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19/BCMA

Regains exclusive rights to IL-12 gene therapy, including application through the AdenoVerse platform.

Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies, amended its exclusive license agreement with Alaunos Therapeutics, Inc. Precigen has the ability to utilize the clinically validated UltraCAR-T platform for unencumbered development and commercialization of two proven CAR-T targets, CD19 and B-cell maturation antigen (BCMA). The targets enhance Precigen’s UltraCAR-T library approach, which is designed to transform the pe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters